In Vivo Pharmacology Across Diverse Therapeutic Areas

Embarking on a transformative journey through diverse therapeutic realms, our in vivo Pharmacology expertise shines as a guiding light. At Evotec, we possess an exceptional understanding of the intricate dynamics that drive various therapeutic areas. With unwavering commitment, our seasoned team navigates the complexities of neurosciences, metabolic diseases, oncology, immuno-oncology, infectious diseases, inflammation, and immunology. Through meticulously designed in vivo studies, we unravel the mysteries of target engagement, establish critical PK/PD relationships, and evaluate the biological impact of potential therapies. Join us as we unlock the potential for groundbreaking advancements in these multifaceted therapeutic domains.

Harnessing our expertise, we excel in evaluating the efficacy of lead and candidate compounds through robust and validated infection models. Our diverse range of well-established models is tailored to the development of various agent classes, such as small molecules, natural products, peptides, antibodies, biologics, and vaccines.

Delivering a highly customized service, we design studies to precisely meet your program's unique requirements. We adapt parameters and endpoints of interest to ensure the most relevant and insightful outcomes.

Partner with us to unlock the potential of your infectious disease research. Benefit from our deep understanding of infection models, allowing you to confidently assess the efficacy of your compounds and drive impactful advancements in the field. 

For efficacy assessment against bacterial and fungal infections, our models address different sites of infection (localized and systemic) and pathogens by:

• Gram-positive (including Staphylococcus aureus, Streptococcus pneumoniae, and others) 
• Gram-negative (including Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumanii and others), anaerobes (including Clostridium difficile) 
• Fungal species (including Candida sp., Aspergillus sp., Mucorales, Malassezia sp.) 

Evotec also specializes in PK/PD profiling and modelling of antimicrobial agents in multiple disease models to understand the key drivers for efficacy and translation of data into clinical trial design. 

Key Read-Outs:

• Burden at site of infection and in multiple biological matrices including quantitative culture, QPCR and biomarkers
• Microbiome analysis and sequencing
• Bioluminescence (IVIS Spectrum) imaging 
• Host response endpoints including ELISA, Western Blotting, dot-blotting, histology, immunohistochemistry, cytokine profiling and cytometry
• Bioanalysis for associated pharmacokinetic studies (PK/PD) and pathogen-associated biomarkers.

Our seasoned team of experts in immunology and inflammation research boasts a proven track record of success. With contributions to the discovery and development of numerous preclinical and clinical candidates, we are at the forefront of innovation. Currently, we are engaged in over 12 dynamic immunology and inflammation programs, covering areas such as inflammation, autoimmune disorders, inflammatory pain, endometriosis, and cancer immunotherapy.

Evotec's core strength lies in small molecule drug discovery for immunology and inflammation, underpinned by extensive expertise. We are constantly expanding our capabilities, with a growing focus on the development of therapeutic antibodies. This state-of-the-art know-how ensures that we remain at the cutting edge of research in these fields.

Partner with our esteemed team to unlock breakthroughs in immunology and inflammation. Benefit from our comprehensive experience, innovative approaches, and relentless pursuit of advancing therapies for these challenging areas. 

• Joint disease (e.g. CIA, MIA) 
• Inflammatory pain (e.g. CFA, NGF) 
• Neuro-inflammation (e.g. Q175, BACHD) 
• Anemia (peptidoglycan-polysaccharide-induce Anemia) 
• Endometriosis 
• Pharmacodynamic/target engagement assays including: LPS/TLR induced cytokine release, IL-1b/desArg9 Bradykinin paw oedema, anti-CD induced T-cell activation and expansion, plus a range of bespoke target/project specific models. 

Key Read-Outs:

• In life clinical measurements: pain, swelling/paw volume, disease activity scoring, automated behavioral analysis (Laboras) 
• Imaging: high-content histology, Bioseb dynamic weight bearing 
• Differential cell counts, full blood chemistry profiling and FACS analysis 
• Quantitative mRNA analysis by RT-qPCR, RNAseq 
• Multi-analyte protein determination in fluids/tissues by MSD and Singulex technology 

Our in vivo pharmacology team possesses robust expertise in supporting drug discovery efforts for metabolic diseases and their complications. At the forefront of innovation, we offer a comprehensive range of well-characterized in vivo models tailored to Type 1 and Type 2 diabetes, obesity, liver disease, and acute and chronic kidney conditions. With a specific focus on NASH and fibrosis, we provide invaluable insights into these critical areas.

Furthermore, our team excels in developing bespoke models customized to meet the unique project requirements of our collaborators.

• Genetic models (e.g., ZDF and ZSF1 rats, db/db and ob/ob mice)
• Streptozotocin (STZ) induced models for Type 1 and Type 2 diabetes, allowing precise control over pancreatic beta cell degradation/loss
• NOD/ShiLtJ mice, an autoimmune-driven Type 1 diabetes model characterized by autoantibodies, pancreatic islet infiltration, and resulting hyperglycemia
• Diet-induced models for insulin resistance, obesity, and NASH

Key Read-Outs:

• Functional glucose/insulin/pyruvate tolerance test 
• Ex vivo read-outs including RT-PCR 
• Biochemical assays 
• Hormonal status and histology 
• Food intake profiles, pair-feeding  
• Body composition analysis by Nuclear Magnetic Resonance (NMR) spectroscopy  
• Morphometric analysis with customized algorithms, quantitative analysis of steatosis, inflammation and fibrosis   
• Histopathologic staging of fibrosis  
• Energy expenditure 

• Acute and chronic renal ischemia reperfusion injury models (aIRI, cIRI) 
• Unilateral ureter obstruction model (UUO) 
• Genetic models of diabetic nephropathy (ZSF1rats, db/db mice) 
• Chemically induced Diabetes mellitus models 

Key Read-Outs:

• Ex vivo read-outs including quantitative RT-PCR 
• Biochemical assays 
• Personalized MSD multiplex- and high-performance validation assays 
• Hormonal status and histology 
• Morphometric analysis with customized algorithms e.g., with pancreas and adipose tissue 
• Quantitative analysis of steatosis, inflammation and fibrosis (state-of-the art histology and image analysis) 
• Histopathologic staging of fibrosis 

Our in vivo pharmacology team possesses robust expertise in supporting drug discovery efforts for metabolic diseases and their complications. At the forefront of innovation, we offer a comprehensive range of well-characterized in vivo models tailored to Type 1 and Type 2 diabetes, obesity, liver disease, and acute and chronic kidney conditions. With a specific focus on NASH and fibrosis, we provide invaluable insights into these critical areas.

Furthermore, our team excels in developing bespoke models customized to meet the unique project requirements of our collaborators.